• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:王冰,王雨廷,李进峰,刘飞,王颖,陈维娜,董浩贞,张媛,孙铜.一线化疗联合贝伐珠单抗治疗晚期非小细胞肺癌的真实世界研究[J].药学研究,2025,44(3):289-295[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2707次   下载 827次 本文二维码信息
码上扫一扫!
一线化疗联合贝伐珠单抗治疗晚期非小细胞肺癌的真实世界研究
王冰1,王雨廷1,李进峰1,刘飞2,王颖1,陈维娜1,董浩贞1,张媛1,孙铜3
字体:加大+|默认|缩小-
(1.山东大学附属威海市立医院,山东 威海 264200;2.山东省食品药品审评查验中心,山东 济南 250022;3.山东省食品药品检验研究院,山东 济南 250101)
摘要:
目的 比较国产生物类似药贝伐珠单抗注射液(安可达)与原研药贝伐珠单抗注射液(安维汀)在治疗晚期非小细胞肺癌患者中的疗效及安全性。方法 选择2020年1月至2021年12月于威海市立医院就诊的肺癌患者,对符合纳入标准的患者进行筛选得到66例,其中化疗方案“培美曲塞+铂类+贝伐珠单抗(安维汀)”为对照组,共28例;“培美曲塞+铂类+贝伐珠单抗(安可达)”为试验组,共38例。把第12周客观缓解率(ORR)作为主要终点, 而18周客观缓解率(ORR)、24周客观缓解率(ORR)、缓解持续时间(DOR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)、安全性评估作为次要终点。结果 66例患者的中位PFS为16周,中位OS为35周;安维汀组患者28例,其中22例患者出现PFS,中位PFS为15周,中位OS为42周;安可达组38例患者,其中的15例患者出现PFS,中位PFS为16周,中位OS为33周。在66名患者的生存函数显示安可达组与安维汀组对患者的生存时间影响未见显著性差异(P>0.05)。COX单因素回归分析,性别、年龄、吸烟史、肿瘤分期以及肿瘤转移部位等因素与PFS、OS均未见显著性关联(P>0.05)。主要研究终点第12周ORR:安维汀组是32.14%,安可达组是65.79%,P=0.007;次要研究终点第18周ORR:安维汀组是21.43%,安可达组是44.74%,P=0.05;第24周ORR:安维汀组是14.29%,安可达组是23.68%,P值是0.343。安维汀组随访结束时ORR 3.57%,DCR 14.29%;安可达组随访结束时ORR 15.79%,DCR 5.26%,两组数据差异无统计学意义(P>0.05)。不良反应共24例,且安可达组与安维汀组发生不良反应的情况无统计学差异。结论 贝伐珠单抗注射液(安可达)在治疗晚期非小细胞肺癌中,有较好的临床疗效及生存获益,不良反应可控、可耐受,临床有效性及安全性较参照药贝伐珠单抗注射液(安维汀)无显著性差异。
关键词:  非小细胞肺癌  贝伐珠单抗注射液  化疗  生物类似药  原研药
DOI:10.13506/j.cnki.jpr.2025.03.013
基金项目:2021年度山东省医学会临床科研资金项目(No.YXH2022ZX02054)
出版日期:2025-03-25
Real-world study of first-line chemotherapy in combination with bevacizumab for advanced non-small cell lung cancer
WANG Bing1,WANG Yuting1,LI Jinfeng1,LIU Fei2,WANG Ying1,CHEN Weina1,DONG Haozhen1,ZHANG Yuan1,SUN Tong3
(1.Department of Pharmacy,Weihai Municipal Hospital, Cheeloo College of Medicine, Shandong University, Weihai 264200, China;2.Shandong Center for Food and Drug Evaluation & Inspection, Jinan 250022,China)
Abstract:
Objective To compare the safety and efficacy of domestic biological analogue Bevacizumab Injection (Ankeda) and the original research drug Bevacizumab Injection (Avastin) in the treatment of advanced non-small cell lung cancer patients.Methods Total of 66 patients with advanced non-small cell lung cancer admitted to Weihai Municipal Hospital from January 2020 to December 2021 were selected, of which 28 patients were treated with the chemotherapy regimen "pemetrexed + platinum + bevacizumab (Avastin)" as the control group and the chemotherapy regimen was "pemetrexed+platinum+bevacizumab (Ankeda)" as the experimental group, with a total of 38 cases. The objective response rate (ORR) at week 12 was used as the primary endpoint, while objective response rates (ORR) at week 18, 24, duration of response (DOR), disease control rate (DCR), progression free survival (PFS), overall survival (OS), and safety assessment were used as secondary endpoints.Results The median PFS was 16 weeks and median OS was 35 weeks in 66 patients; 28 patients in the Avastin group, of whom 22 had PFS, median PFS of 15 weeks, and median OS of 42 weeks; And 38 patients in the Ankeda group, of whom 15 had PFS, median PFS of 16 weeks, and median OS of 33 weeks. In the survival function of 66 patients, there was no significant difference in the effect of time to survival between the Ankeda and Avastin groups (P>0.05), and no significant association was found between sex, age, smoking history, tumor stage and metastatic site on PFS and OS in the COX one-way regression analysis (P>0.05). The main endpoint of the 12th week ORR study was 32.14% in the Avastin group and 65.79% in the Ankeda group(P=0.007); The ORR of the secondary study endpoint at week 18 was 21.43% in the Avastin group and 44.74% in the Ankeda group (P =0.05); The ORR for the 24th week was 14.29% in the Avastin group and 23.68% in the Ankeda group(P=0.343). The patients in the Avastin group had an ORR of 3.57% and a DCR of 14.29% at the end of follow-up。And at the end of follow-up, patients in the Ankeda group had an ORR of 15.79% and a DCR of 5.26%, with no statistically significant difference between the two groups (P>0.05). Among the 66 patients, there were 24 cases of adverse reactions. And there was no statistically significant difference between the occurrence of adverse reactions in the Ankeda and Avastin groups. Conclusion Bevacizumab Injection (Ankeda) has excellent clinical efficacy and survival advantages in the treatment of advanced non-small cell lung cancer with controlled and tolerable adverse effects.There is no statistically significant difference in clinical efficacy and safety compared to the reference drug bevaczumab injection (Avastin).
Key words:  Non-small cell lung cancer  Bevacizumab injection  Chemotherapy  Biosimilar drugs  Original research drug
今日访问量:2644    总访问量:55339159
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司